Evidence map›Paper›PMID 42131842›Full record

ReviewFrontiers in chemistry2026

Strategic applications of heterocyclic compounds in pharmaceutical innovation: a business perspective.

Yan Dong, Jindong Dai, Yuerong Zou, Kanagaraj Rajalakshmi, Natarajan Kiruthiga, P Balaji, Dongwei Zhu

Abstract readReview
In one paragraph

Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan DongDepartment of Immunology and Laboratory Medicine, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.
Jindong DaiDepartment of Immunology and Laboratory Medicine, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.
Yuerong ZouDepartment of Immunology and Laboratory Medicine, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.
Kanagaraj RajalakshmiSchool of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang, China.
Natarajan KiruthigaDepartment of Pharmaceutical Chemistry, KMCH College of Pharmacy, Coimbatore, Tamil Nadu, India.
P BalajiDepartment of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India.
Dongwei ZhuDepartment of Immunology and Laboratory Medicine, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The heterocyclic compound is one of the finest spanned backbones for developing most innovative agents in the pharmaceutical industry. These adaptable molecules have played an important role in the discovery of therapeutic agents of a wide range, including antibiotics, anticancer drugs and antivirals. The role of heterocyclic chemistry in pharmaceutical innovation is thus one that extends beyond mere structural complexity but contributes significantly to improved therapeutic index, and in doing so stimulates economic activity in the field. The medicinal significance of heterocycles, their role in drug discovery, and their commercial prospects are discussed in the Research article. It explores types of heterocyclic compounds, its historical importance, influence on the world health and market trends delivering its industrial usage. Synthetic challenges, regulatory hurdles, and sustainability concerns are discussed in tandem with future opportunities that may arise from advancements in green synthesis and artificial intelligence (AI)-driven drug discovery. This study emphasizes the transformative potential of heterocyclic compounds in modern medicine by connecting their scientific advancements to business strategies.

Indexed as

business strategydrug developmentheterocyclic chemistrymarket analysismedicinal chemistrypharmaceutical innovationsustainability

Identifiers

PMID42131842
PMCPMC13160906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.